Evaluation of efficacy of a biofilm-embedded bacteria-based vaccine against staphylococcal mastitis in sheep-A randomized, placebo-controlled field study.


Journal

Journal of dairy science
ISSN: 1525-3198
Titre abrégé: J Dairy Sci
Pays: United States
ID NLM: 2985126R

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 12 01 2019
accepted: 30 05 2019
pubmed: 12 8 2019
medline: 18 12 2019
entrez: 12 8 2019
Statut: ppublish

Résumé

Our objective was to evaluate the efficacy of a vaccine against staphylococcal mastitis in 5 dairy sheep farms, with 316 ewes in the vaccinated (V) group and 307 in the control (C) group studied throughout a lactation period. Two administrations of the vaccine were performed during the last stage of gestation of ewes. Starting 15 d after lambing and at monthly intervals thereafter, up to 9 milk samplings were performed for bacteriological and cytological examinations. Staphylococcal isolates recovered were examined for biofilm formation. Blood samples were collected for measurement of IgG poly-N-acetylglucosamine-specific antibodies. The most frequently isolated bacteria were staphylococci: 56.4 and 76.1%, respectively, of total isolates recovered from ewes of group V and C, respectively; staphylococci as causal agents of mastitis were isolated less frequently from V (5.3%) than in ewes in C (10.3%). Among mastitis-associated staphylococcal isolates recovered from V ewes, a smaller proportion was biofilm-forming than among ones from C: 53.2% versus 74.9% of isolates; biofilm-forming staphylococci as causal agents of mastitis were isolated less frequently from ewes in group V (2.3%) than in ewes in group C (6.0%). Anti-poly-N-acetylglucosamine-specific antibody values increased in V ewes and were higher than in C; a greater proportion of ewes with low antibody titers developed staphylococcal mastitis (41.4%) than of V ewes with high antibody titers (17.0%). Incidence risk of mastitis, staphylococcal mastitis, and biofilm-associated staphylococcal mastitis was smaller in V than in C: 36.7, 17.1, and 8.0% versus 44.3, 30.9, and 18.9%, respectively. The first case of staphylococcal mastitis occurred later in V than in C: third versus second sampling point. Overall, efficacy of the vaccine was 44.6% for staphylococcal mastitis, 57.7% for biofilm-associated staphylococcal mastitis, 33.1% for staphylococcal intramammary infection, and 51.5% for biofilm-associated staphylococcal intramammary infection. Nevertheless, vaccination should not be the only means for controlling mastitis; other udder health management measures should be included therein to improve control of the infection.

Identifiants

pubmed: 31400892
pii: S0022-0302(19)30678-2
doi: 10.3168/jds.2019-16287
pii:
doi:

Substances chimiques

Bacterial Vaccines 0

Types de publication

Clinical Trial, Veterinary Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9328-9344

Informations de copyright

The Authors. Published by FASS Inc. and Elsevier Inc. on behalf of the American Dairy Science Association®. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Auteurs

N G C Vasileiou (NGC)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

D C Chatzopoulos (DC)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

P J Cripps (PJ)

Institute of Veterinary Science, University of Liverpool, Neston, South Wirral, CH64 7TE, United Kingdom.

K S Ioannidi (KS)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

D A Gougoulis (DA)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

T M Chouzouris (TM)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

D T Lianou (DT)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

T Calvo Gonzalez-Valerio (TC)

Laboratorios Hipra S.A., 17170 Amer (Girona), Spain.

R Guix Vallverdu (RG)

Laboratorios Hipra S.A., 17170 Amer (Girona), Spain.

S Argyros (S)

Laboratorios Hipra S.A., 17170 Amer (Girona), Spain.

M Cesio (M)

Laboratorios Hipra S.A., 17170 Amer (Girona), Spain.

I Font (I)

Laboratorios Hipra S.A., 17170 Amer (Girona), Spain.

V S Mavrogianni (VS)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece.

E Petinaki (E)

University Hospital of Larissa, 41110 Larissa, Greece.

G C Fthenakis (GC)

Veterinary Faculty, University of Thessaly, 43100 Karditsa, Greece. Electronic address: gcf@vet.uth.gr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH